2 unknown, 1 not yet recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Not yet recruiting 1 |
Follow Tarapeutics Science Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TR115 in ARID1A-Mutated Advanced Solid Tumors TR115 - Ovarian Clear Cell Carcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Tarapeutics Science Inc. | 50 | 2026-09-20 | 2026-08-28 |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122; cytarabine - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 18 | 2022-03-29 | 2025-04-10 |
| A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122 - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 15 | 2021-09-29 | 2024-05-14 |
Leukemia, Myeloid, Acute (2) · Recurrence (2) · Endometrial Neoplasms (1) · Urinary Bladder Neoplasms (1)
Cytarabine (1)
China (3)